The Radiation Therapy Quality Assurance Phantoms Market Size is valued at 28.94 Million in 2023 and is predicted to reach 47.34 Million by the year 2031 at a 6.52 % CAGR during the forecast period for 2024-2031.
One medical discipline that uses radiation to treat cancer is radiation oncology. As part of quality control methods, the machines are tested daily, monthly, and annually using phantoms. In the realm of medical imaging, phantoms are specially created objects that are utilized for the testing, grading, and calibration of various imaging equipment. Dose calibration, beam calibration, patient location, and treatment planning system are a few of the main areas examined during quality assurance using phantoms. The rising prevalence of diseases like cancer is anticipated to fuel the growth of the radiation therapy quality assurance phantoms market. Innovative imaging phantoms are in high demand due to the rise in diagnostic imaging facilities and the requirement for in-house calibration methods.
The growing need for improved phantoms is anticipated to be significantly influenced by the increased prevalence of diseases such as chronic ailments, cancers of all kinds, and heart failure. These phantoms can aid in examining the possibilities of imaging systems' early detection capabilities. Therefore, it is anticipated that using radiation therapy quality assurance phantoms to increase the effectiveness of equipment like X-rays, CT scan, and MRI will significantly contribute to market growth.
The market for radiation therapy quality assurance phantoms, on the other hand, is predicted to increase slowly over the timeline because of the rise in concerns over costs. The market for radiation treatment quality assurance phantoms is confronted with several problems, including greater end-user knowledge of safety and reliability procedures and strict government restrictions, which could somewhat restrain its global demand in the next few years.
Market Segmentation:
The radiation therapy quality assurance phantoms market is segmented on the basis of technology and therapy. Based on technology, the market is characterized by linear accelerators, cobalt-60, high-dose radiation, and low-dose radiation. Based on therapy, the market is characterized by external radiation therapy (Photon Beam Radiation Therapy, Advanced three-Dimensional Conformal Radiation Therapy (3-D CRT), Volumetric Modulated Arc Therapy (VMAT), Image Guided Radiation Therapy (IGRT), Stereotactic Radiation Therapy, Intraoperative Radiotherapy (IORT), Proton Beam Therapy & Neutron Beam Therapy) and internal radiation therapy or brachytherapy.
Based On Technology, The Linear Accelerator Segment Is Accounted As A Major Contributor In The Radiation Therapy Quality Assurance Phantoms Market
The linear accelerator sector held the largest market share. The increased cancer incidence and product technological advancements are expected to drive the medical linear accelerator industry's expansion. Additionally, most cancers are found after they are well advanced. So, as the prevalence of cancer rises, will a need for therapy, which is expected to drive the growth of the medical linear accelerator market. High-energy x-rays are used in medical linear accelerators to kill cancerous cells and tumors while sparing nearby healthy tissues. The growing use of machine learning (ML) and artificial intelligence (AI) is transforming the market, primarily by increasing the effectiveness of cancer therapy with devices like linear accelerators.
The Internal Radiation Therapy Or Brachytherapy Segment Witnessed Growth At A Rapid Rate.
Brachytherapy is the type of radiation therapy that is most frequently used to treat cancer. Radiation therapy for the treatment of cancer includes brachytherapy. Catheters are used to insert radioactive materials into the body. Breast, head and neck, cervix, prostate, and ocular malignancies can all be treated with it. Following the planning of the treatment processes, brachytherapy quality assurance phantoms are used to assess area and volume, depth of penetration, distance, axial and lateral resolution, and geometric consistency. Additionally, the growing popularity of less invasive procedures will likely present more chances for the brachytherapy industry to expand in the coming years.
In The Region, The North American Radiation Therapy Quality Assurance Phantoms Market Holds A Significant Revenue Share.
During the forecast period, North America dominated the market, with the US and Canada accounting for most of the industry's revenue. This is primarily due to the country's sophisticated healthcare infrastructure, government support for growing the number of medical imaging devices to boost this industry's efficiency, growth in imaging device sales, and patient-centric philosophy. The substantial presence of significant medical technology companies, the rise in the use of radiotherapy equipment, and the growing emphasis on developing cutting-edge technologies and methodical radiation therapy for better patient care in the region are all variables that contribute to the rapid growth. In addition, Asia Pacific is anticipated to experience a CAGR in revenue that is noticeably higher. Government funding and increased R&D efforts are leading to the creation and adoption of more effective solutions, fueling the global market's revenue expansion. Other significant driving forces include expanding public awareness of the advantages of utilizing cutting-edge technologies to improve patient care and evaluate radiation therapy quality, rising cancer prevalence, and, most significantly, increasing demand for phantoms.
Competitive Landscape
Some Major Key Players In The Radiation Therapy Quality Assurance Phantoms Market:
- Computerized Imaging Reference Systems, Inc.
- Fluke Biomedical
- IBA Dosimetry
- Modus Medical Devices Inc.
- PTW Freiburg GmbH
- Standard Imaging Inc.
- Sun Nuclear Corporation
- The Phantom Laboratory, In.
Radiation Therapy Quality Assurance Phantoms Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 28,94 Million |
|
Revenue Forecast In 2031 |
USD 47.34 Million |
|
Growth Rate CAGR |
CAGR of 6.52 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Technology, Therapy |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Computerized Imaging Reference Systems, Inc., Fluke Biomedical, IBA Dosimetry, Modus Medical Devices Inc., PTW Freiburg GmbH, Standard Imaging Inc., Sun Nuclear Corporation and The Phantom Laboratory, In |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
